Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid

AIMS: Irritability has been described as a frequent adverse event in patients affected by epilepsy and treated with perampanel (PER), levetiracetam (LEV), and less frequently with valproic acid (VPA). Since the questionnaire for irritability (I‐EPI) is a validated instrument to measure this psychiat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liguori, Claudio, Turner, Katherine, Izzi, Francesca, Assogna, Martina, Canevini, Maria P., Mercuri, Nicola B., Placidi, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488879/
https://www.ncbi.nlm.nih.gov/pubmed/30675751
http://dx.doi.org/10.1111/cns.13098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488879/
https://www.ncbi.nlm.nih.gov/pubmed/30675751
http://dx.doi.org/10.1111/cns.13098

Ejemplares similares